MIAMI – The first large-scale clinical trial of a cannabis derivative known as cannabidiol shows it was able to cut the frequency of severe epileptic seizures by 39 percent, researchers said Wednesday. Cannabidiol, or CBD, is derived from cannabis plants, but does not cause users to get high. The study in the New England Journal […]

Doctors who treat Dravet syndrome can’t stop their patients’ seizures—but a chemical in weed may help. Dravet syndrome is a rare, genetic form of epilepsy that affects less than one in 16,000 children. It’s diagnosed when infants who are perfectly healthy start having seizures around their first birthday. From there, doctors can prescribe medications that […]

The first large-scale clinical trial of a cannabis derivative known as cannabidiol shows it was able to cut the frequency of severe epileptic seizures by 39 percent, researchers said Wednesday. Cannabidiol, or CBD, is derived from cannabis plants, but does not cause users to get high. The study in the New England Journal of Medicine […]

A marijuana-based drug has shown promising results as a treatment for a rare and deadly form of epilepsy in its first large-scale clinical trial. In the randomized trial of the cannabis derivative, cannabidiol, scientists showed a significant reduction in seizures among children suffering from Dravet syndrome—a complex disease that leads to developmental problems and has […]

A landmark clinical trial has shown that a compound in marijuana can ease life-threatening seizures in children with a rare and devastating form of epilepsy. Cannabidiol — a non-intoxicating chemical — reduced seizure frequency by 39 percent in patients with Dravet Syndrome, researchers report. This is the first randomized, controlled trial to show that cannabidiol […]

London (ots/PRNewswire) – – Pharmazeutische Cannabidiol-Formulierung reduziert signifikant die Hufigkeit von Krampfanfllen bei Kindern, die schlecht auf Behandlung mit multiplen Antiepileptika ansprechen – – Erste ordnungsgem kontrollierte klinische Studie zu Cannabidiol beim Dravet-Syndrom, einer seltenen, schweren Form der Epilepsie, fr die keine von der FDA-zugelassene Therapie vorliegt – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW”, “das […]

– Pharmaceutical formulation of cannabidiol significantly reduced convulsive seizure frequency in children on multiple anti-epileptic drugs with poor seizure control – – First well-controlled clinical study of cannabidiol in Dravet syndrome, a rare, severe type of epilepsy with no FDA-approved treatments – LONDON, May 24, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or […]

WeatherBFN: min: 7° max: 22°, cloudyCPT: min: 13° max: 20°, cloudyDBN: min: 20° max: 23°, sunnyEL: min: 17° max: 21°, cloudyJHB: min: 7° max: 22°, sunnyKIM: min: 11° max: 25°, sunnyNLP: min: 10° max: 26°, cloudyPMB: min: 7° max: 21°, cloudyPE: min: 16° max: 19°, cloudyPTA: min: 7° max: 23°, sunny … read more at: […]

Guest Editors Jerzy Szaflarski, MD, PhD, Director of the Epilepsy Center, University of Alabama at Birmingham, and Orrin Devinsky, MD, Director, Epilepsy Center, New York University Langone Medical Center, New York, comment that, “There is an enormous dissociation between the widespread use of cannabis-based therapies to treat diverse epilepsies and our understanding about the efficacy […]